Qingping Yao

Dr. Qingping Yao

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2017 in The American Journal of Medicine
Verified
Journal Article
Closed access
QYQingping Yao
Qingping Yao
BSBo Shen
Bo Shen

10 September 2020 in Current Cardiology Reports
Verified
Journal Article
Closed access
PDF file
AKApostolos Kontzias
Apostolos Kontzias
ABAmir Barkhodari
Amir Barkhodari
QYQingping Yao
Qingping Yao

1 August 2020 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
SSSaika Sharmeen
Saika Sharmeen
AEAhmed Elghawy
Ahmed Elghawy
FZFnu Zarlasht
Fnu Zarlasht
QYQingping Yao
Qingping Yao

21 December 2022 in Trends in Genetics
Verified
Journal Article
Closed access
QYQingping Yao
Qingping Yao
PGPeter Gorevic
Peter Gorevic
BSBo Shen
Bo Shen
Greg GibsonGreg Gibson
Greg Gibson

17 February 2019 in Autoimmunity
Verified
Journal Article
Closed access
QYQingping Yao
Qingping Yao
ELEllen Li
Ellen Li
BSBo Shen
Bo Shen
Systemic autoinflammatory diseases (SAIDs) represent a spectrum of genetically heterogeneous inflammatory disorders. Some SAID-associated genes are located in chromosome 16, including familial Mediterranean fever gene (MEFV) and nucleotide-binding oligomerization domain 2 [NOD2] gene that are linked to Crohn’s disease, Blau syndrome, and Yao syndrome. These disorders share overlapping clinical phenotypes, and genotyping is diagnostically helpful and distinctive. Using next generation sequencing in SAIDs, digenic variants or combinations of more genetic variants in different genes can be detected, and they may be related to the MEFV and NOD2 genes. These variants may contribute to heterogeneous phenotypes in an individual, complicating the diagnosis and therapy. An awareness of the clinical significance of the digenic or combined gene variants is important in the era of genomic medicine.

17 February 2018 in Autoimmunity
Verified
Journal Article
Closed access
CMChristine McDonald
Christine McDonald
MSMin Shen
Min Shen
EJErin Johnson
Erin Johnson
AKAmrita Kabi
Amrita Kabi
QYQingping Yao
Qingping Yao
Yao syndrome (YAOS) is a systemic autoinflammatory disease (SAID), formerly termed nucleotide-binding oligomerization domain-2 (NOD2)-associated autoinflammatory disease. Due to the recent identification of YAOS, the molecular mechanisms underlying its disease pathogenesis are unclear. With specific NOD2 variants as characteristic genotypic features of YAOS, our study examined NOD2 expression, transcript splicing, signaling pathway activation, and cytokine profiles in peripheral blood mononuclear cells (PBMCs) from 10 YAOS patients and six healthy individuals. All participants were genotyped for NOD2 variants; all YAOS patients were heterozygous for the NOD2 IVS8+158 variant (IVS8+158) and four patients also carried a concurrent NOD2 R702W variant (IVS8+158/R702W haplotype). Resembling other SAIDs, plasma levels of TNFα, IL-1β, IL-6, IFNγ, and S100A12 were unaltered in YAOS patients. Intron-8 splicing of NOD2 transcripts was unaffected by carriage of NOD2 IVS8+158. However, NOD2 transcript level and basal p38 mitogen-activated protein kinase (MAPK) activity were significantly elevated in PBMCs from IVS8+158 YAOS patients. Moreover, these patients’ cells had elevated basal IL-6 secretion that was enhanced by muramyl dipeptide (MDP) stimulation. Tocilizumab treatment of a YAOS IVS8+158 patient resulted in marked clinical improvement. In contrast, MDP-stimulated NF-κB activity was uniquely suppressed in haplotype IVS8+158/R702W patients, as was TNFα secretion. Our study demonstrates for the first time that NOD2 expression and pathway activation are aberrant in YAOS, and specific NOD2 genotypes result in distinct NOD2 expression and cytokine profiles. These findings may also help select therapeutic strategies in the future.